AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. DGX
  4. [Form 4] Quest Diagnostics Inc. Insider Trading Activity

[Form 4] Quest Diagnostics Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Patrick Plewman, Senior Vice President for Diagnostic Services at Quest Diagnostics Inc. (DGX), reported an insider sale under a Rule 10b5-1 plan. On 08/21/2025 he disposed of 1,975 shares of Quest Diagnostics common stock at $185 per share. Following the transaction, he beneficially owned 15,269 shares, held directly. The filing indicates the sale was executed pursuant to an established 10b5-1 trading plan and the Form 4 was signed by an attorney-in-fact on 08/25/2025. No derivative transactions or other securities were reported in this filing.

Patrick Plewman, Senior Vice President per i servizi diagnostici di Quest Diagnostics Inc. (DGX), ha comunicato una vendita da insider nell鈥檃mbito di un piano 10b5-1. In data 21/08/2025 ha ceduto 1.975 azioni ordinarie di Quest Diagnostics al prezzo di $185 per azione. Dopo l鈥檕perazione deteneva direttamente in via beneficiaria 15.269 azioni. Il documento indica che la vendita 猫 stata effettuata secondo un piano di negoziazione 10b5-1 previamente stabilito e che il Modulo 4 猫 stato firmato da un procuratore il 25/08/2025. Non sono riportate operazioni su derivati n茅 altri strumenti finanziari in questo deposito.

Patrick Plewman, vicepresidente senior de servicios diagn贸sticos en Quest Diagnostics Inc. (DGX), inform贸 una venta de insider bajo un plan 10b5-1. El 21/08/2025 dispuso de 1.975 acciones ordinarias de Quest Diagnostics a $185 por acci贸n. Tras la operaci贸n pose铆a beneficiosamente, en propiedad directa, 15.269 acciones. La presentaci贸n indica que la venta se ejecut贸 conforme a un plan de negociaci贸n 10b5-1 establecido y que el Formulario 4 fue firmado por un apoderado el 25/08/2025. No se informaron transacciones con derivados ni otros valores en este informe.

韺姼毽� 頂岆毹�鞚� Quest Diagnostics Inc.(DGX)鞚� 歆勲嫧靹滊箘鞀� 靾橃劃 攵�靷灔鞙茧靹� 10b5-1 瓿勴殟鞐� 霐半ジ 雮措秬鞛� 毵る弰毳� 氤搓碃頄堨姷雼堧嫟. 2025雲� 8鞗� 21鞚检棎 Quest Diagnostics 氤错喌欤� 1,975欤�毳� 欤茧嫻 $185鞐� 觳橂秳頄堨姷雼堧嫟. 瓯半灅 頉� 攴鸽姅 歆侅爲 靻岇湢 順曧儨搿� 15,269欤�毳� 鞁れ 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 鞚� 毵る弰臧� 靷爠鞐� 靹れ爼霅� 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃鞙茧┌, 鞏戩嫕(Form 4)鞚� 雽�毽澑鞚� 2025雲� 8鞗� 25鞚� 靹滊獏頃� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤� 鞝滌稖靹滊鞐愲姅 韺岇儩靸來拡 瓯半灅 霕愲姅 旮绊儉 歃濌秾 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Patrick Plewman, vice鈥憄r茅sident principal des services diagnostiques chez Quest Diagnostics Inc. (DGX), a d茅clar茅 une cession par initi茅 r茅alis茅e dans le cadre d鈥檜n plan 10产5鈥�. Le 21/08/2025, il a c茅d茅 1 975 actions ordinaires de Quest Diagnostics au prix de 185 $ par action. 脌 la suite de la transaction, il d茅tenait b茅n茅fi颅ciairement et directement 15 269 actions. Le d茅p么t indique que la vente a 茅t茅 effectu茅e conform茅ment 脿 un plan de n茅gociation 10产5鈥�1 茅tabli et que le formulaire 4 a 茅t茅 sign茅 par un mandataire le 25/08/2025. Aucune transaction sur d茅riv茅s ni autre instrument financier n鈥檈st mentionn茅e dans ce d茅p么t.

Patrick Plewman, Senior Vice President f眉r diagnostische Dienstleistungen bei Quest Diagnostics Inc. (DGX), meldete einen Insiderverkauf im Rahmen eines 10b5-1-Plans. Am 21.08.2025 ver盲u脽erte er 1.975 Aktien der Quest Diagnostics-Stammaktien zu $185 je Aktie. Nach der Transaktion besa脽 er direkt und wirtschaftlich 15.269 Aktien. Die Einreichung gibt an, dass der Verkauf gem盲脽 eines zuvor eingerichteten 10b5-1-Handelsplans ausgef眉hrt wurde und dass das Formular 4 am 25.08.2025 von einem Bevollm盲chtigten unterzeichnet wurde. In dieser Meldung wurden keine Derivatgesch盲fte oder sonstigen Wertpapiere angegeben.

Positive
  • Transaction executed under a Rule 10b5-1 plan, indicating a pre-established trading plan
  • Clear disclosure of amounts: 1,975 shares sold at $185 and 15,269 shares retained
  • Form signed and filed (attorney-in-fact signature dated 08/25/2025), demonstrating compliance with reporting rules
Negative
  • None.

Insights

TL;DR: Routine insider sale under a 10b5-1 plan; no governance red flags disclosed.

The filing shows a common-stock sale by a senior officer executed under a Rule 10b5-1 plan, which provides an affirmative defense to insider trading allegations when properly adopted. The report lists the exact share count sold (1,975) and remaining beneficial ownership (15,269), and it is signed by an attorney-in-fact, indicating administrative handling. There are no indications of material non-routine events, related-party transactions, or amendments that would suggest governance concerns in this disclosure.

TL;DR: Transaction is informational for holders but likely immaterial to company fundamentals.

The sale of 1,975 shares at $185 is a discrete insider liquidity event reported on Form 4. Because it was executed under a pre-established 10b5-1 plan and leaves the reporting person with 15,269 shares, this appears to be routine insider selling rather than a reaction to undisclosed company developments. The filing contains no new financial metrics or operational changes that would affect valuation models.

Patrick Plewman, Senior Vice President per i servizi diagnostici di Quest Diagnostics Inc. (DGX), ha comunicato una vendita da insider nell鈥檃mbito di un piano 10b5-1. In data 21/08/2025 ha ceduto 1.975 azioni ordinarie di Quest Diagnostics al prezzo di $185 per azione. Dopo l鈥檕perazione deteneva direttamente in via beneficiaria 15.269 azioni. Il documento indica che la vendita 猫 stata effettuata secondo un piano di negoziazione 10b5-1 previamente stabilito e che il Modulo 4 猫 stato firmato da un procuratore il 25/08/2025. Non sono riportate operazioni su derivati n茅 altri strumenti finanziari in questo deposito.

Patrick Plewman, vicepresidente senior de servicios diagn贸sticos en Quest Diagnostics Inc. (DGX), inform贸 una venta de insider bajo un plan 10b5-1. El 21/08/2025 dispuso de 1.975 acciones ordinarias de Quest Diagnostics a $185 por acci贸n. Tras la operaci贸n pose铆a beneficiosamente, en propiedad directa, 15.269 acciones. La presentaci贸n indica que la venta se ejecut贸 conforme a un plan de negociaci贸n 10b5-1 establecido y que el Formulario 4 fue firmado por un apoderado el 25/08/2025. No se informaron transacciones con derivados ni otros valores en este informe.

韺姼毽� 頂岆毹�鞚� Quest Diagnostics Inc.(DGX)鞚� 歆勲嫧靹滊箘鞀� 靾橃劃 攵�靷灔鞙茧靹� 10b5-1 瓿勴殟鞐� 霐半ジ 雮措秬鞛� 毵る弰毳� 氤搓碃頄堨姷雼堧嫟. 2025雲� 8鞗� 21鞚检棎 Quest Diagnostics 氤错喌欤� 1,975欤�毳� 欤茧嫻 $185鞐� 觳橂秳頄堨姷雼堧嫟. 瓯半灅 頉� 攴鸽姅 歆侅爲 靻岇湢 順曧儨搿� 15,269欤�毳� 鞁れ 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 鞚� 毵る弰臧� 靷爠鞐� 靹れ爼霅� 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃鞙茧┌, 鞏戩嫕(Form 4)鞚� 雽�毽澑鞚� 2025雲� 8鞗� 25鞚� 靹滊獏頃� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤� 鞝滌稖靹滊鞐愲姅 韺岇儩靸來拡 瓯半灅 霕愲姅 旮绊儉 歃濌秾 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Patrick Plewman, vice鈥憄r茅sident principal des services diagnostiques chez Quest Diagnostics Inc. (DGX), a d茅clar茅 une cession par initi茅 r茅alis茅e dans le cadre d鈥檜n plan 10产5鈥�. Le 21/08/2025, il a c茅d茅 1 975 actions ordinaires de Quest Diagnostics au prix de 185 $ par action. 脌 la suite de la transaction, il d茅tenait b茅n茅fi颅ciairement et directement 15 269 actions. Le d茅p么t indique que la vente a 茅t茅 effectu茅e conform茅ment 脿 un plan de n茅gociation 10产5鈥�1 茅tabli et que le formulaire 4 a 茅t茅 sign茅 par un mandataire le 25/08/2025. Aucune transaction sur d茅riv茅s ni autre instrument financier n鈥檈st mentionn茅e dans ce d茅p么t.

Patrick Plewman, Senior Vice President f眉r diagnostische Dienstleistungen bei Quest Diagnostics Inc. (DGX), meldete einen Insiderverkauf im Rahmen eines 10b5-1-Plans. Am 21.08.2025 ver盲u脽erte er 1.975 Aktien der Quest Diagnostics-Stammaktien zu $185 je Aktie. Nach der Transaktion besa脽 er direkt und wirtschaftlich 15.269 Aktien. Die Einreichung gibt an, dass der Verkauf gem盲脽 eines zuvor eingerichteten 10b5-1-Handelsplans ausgef眉hrt wurde und dass das Formular 4 am 25.08.2025 von einem Bevollm盲chtigten unterzeichnet wurde. In dieser Meldung wurden keine Derivatgesch盲fte oder sonstigen Wertpapiere angegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Plewman Patrick
(Last) (First) (Middle)
500 PLAZA DRIVE
C/O QUEST DIAGNOSTICS INC
(Street)
SECAUCUS NJ 07094
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP for Diagnostic Services
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/21/2025 S(1) 1,975 D $185 15,269 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Remarks:
Sean D. Mersten, Attorney in Fact for Patrick Plewman 08/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider transaction did Patrick Plewman report for DGX?

He reported the sale of 1,975 shares of Quest Diagnostics common stock on 08/21/2025 at $185 per share.

Was the sale by Patrick Plewman part of a 10b5-1 plan?

Yes, the Form 4 states the sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

How many Quest Diagnostics shares does Plewman own after the reported transaction?

Following the reported transaction, he beneficially owned 15,269 shares, held directly.

Who signed the Form 4 filing on behalf of Patrick Plewman?

The Form 4 shows it was signed by Sean D. Mersten, Attorney in Fact for Patrick Plewman on 08/25/2025.

Does this Form 4 disclose any options or derivative transactions for DGX?

No. Table II for derivative securities contains no reported transactions; only a common stock sale is listed in Table I.
Stock DGX logo
Quest Diagnostics Inc

NYSE:DGX

DGX Rankings

#583 Ranked by Market Cap
#1659 Ranked by Dividends

DGX Latest News

Aug 25, 2025
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
Aug 15, 2025
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference
Aug 13, 2025
Quest Diagnostics Declares Quarterly Cash Dividend
Aug 7, 2025
Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types
Aug 5, 2025
Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care

DGX Latest SEC Filings

Aug 21, 2025
[Form 4] Quest Diagnostics Inc. Insider Trading Activity
Aug 21, 2025
[144] Quest Diagnostics Inc. SEC Filing
Aug 19, 2025
[Form 4] Quest Diagnostics Inc. Insider Trading Activity
Aug 19, 2025
[144] Quest Diagnostics Inc. SEC Filing
Aug 15, 2025
[144] Quest Diagnostics Inc. SEC Filing

DGX Stock Data

20.15B
111.32M
0.4%
99.13%
4.24%
Diagnostics & Research
Services-medical Laboratories
United States
SECAUCUS